X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The OK-101 drug candidate displays potent anti-inflammatory activity in animal models of DED. OK-101 also reduces Corneal Neuropathic Pain (CNP) in a ciliary nerve ligation animal model of CNP.
Lead Product(s): OK-101
Therapeutic Area: Ophthalmology Product Name: OK-101
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: OKYO Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
Amytrx has identified new opportunities for other inflammatory and metabolic diseases with attractive out-licensing and collaborative opportunities using its proprietary AMTX-100 human peptide platform.
Lead Product(s): AMTX-100
Therapeutic Area: Dermatology Product Name: AMTX-100
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Recipient: Amytrx Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 26, 2022
Details:
ONL1204 Ophthalmic Solution is a novel, first-in-class small peptide Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and conditions.
Lead Product(s): ONL1204
Therapeutic Area: Ophthalmology Product Name: ONL1204
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: ONL Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Details:
Icatibant, a complex injectable peptide product, forming part of high-value product, is an equivalent and more affordable version of Firazyr (Takeda/Shire), used used to treat a serious orphan disease, acute attacks of hereditary angioedema.
Lead Product(s): Icatibant Acetate
Therapeutic Area: Genetic Disease Product Name: Icatibant Acetate-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Adalvo
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
Researchers have utilized a venom peptide originally isolated from the Peruvian green velvet tarantula (Thrixopelma pruriens) that blocks Nav1.7 voltage-gated ion channels, an ion channel important in pain signaling.
Lead Product(s): Thrixopelma pruriens venom peptide
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Peptide
Recipient: University of California
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2021
Details:
AmbioPharm will manufacture the active pharmaceutical ingredient exclusively for Upsher-Smith. A contract manufacturing organization will exclusively supply Upsher-Smith with the finished product for sale in the United States.
Lead Product(s): Corticotropin
Therapeutic Area: Neurology Product Name: Acthar
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Upsher-Smith Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 07, 2020
Details:
The partnership includes a basket of difficult-to-make peptide products that will be used to treat various diseases, ranging from diabetes to immunology disorders, cardiologic and endocrinology diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Peptide
Recipient: Adalvo
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
